{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:28Z","timestamp":1786119928706,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/mjt.0b013e31820b8846","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T03:53:05Z","timestamp":1303789985000},"page":"73-78","source":"Crossref","is-referenced-by-count":6,"title":["Tuberculosis Infections and Tumor Necrosis Factor Alpha Antagonists"],"prefix":"10.1097","volume":"20","author":[{"given":"Justin","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine M.","family":"Manadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Sequiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210202","first-page":"289","article-title":"Decrease in reported tuberculosis cases--United States, 2009.","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R2-13-20210202","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":". Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.27271","article-title":". Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.","volume":"62","author":"Lin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":". Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-13-20210202","first-page":"1","article-title":"Summary of notifiable diseases, United States, 1999.","volume":"48","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R7-13-20210202","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":". Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":". Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R10-13-20210202","first-page":"1436","article-title":"; EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis.","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":". Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R13-13-20210202","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis.","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R14-13-20210202","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":". Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry.","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R18-13-20210202","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3899\/jrheum.081041","article-title":". Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"; BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R20-13-20210202","first-page":"1127","article-title":". Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"R21-13-20210202","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3899\/jrheum.090149","article-title":". Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.","volume":"36","author":"Ekochin","year":"2009","journal-title":"J Rheumatol"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2007.076406","article-title":"3rd, Kishimoto M, et al.. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic.","volume":"67","author":"Mor","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R23-13-20210202","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/ard.2002.004598","article-title":". High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors.","volume":"62","author":"Vanhoof","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-201301000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:29:21Z","timestamp":1786044561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201301000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31820b8846","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}